BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed HROW catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:b3821927e6ad62a57077@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:HROW P3 readout (est.): A Phase 3 Study Evaluating the Safety and E
 fficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular
  Inflammation and Pain After Ophthalmic Surgery
DESCRIPTION:A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE
 ® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pa
 in After Ophthalmic Surgery\nNCT07832552 | PHASE3 | ENROLLING_BY_INVITATIO
 N | sponsor: Harrow Inc\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nDate precision: month (shown on the first day
 )\nTicker HROW (confidence 0.9)\nSource: https://clinicaltrials.gov/study/
 NCT07832552\nScheduling/reference data from public records\; dates can mov
 e. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07832552
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
